Etoricoxib is used to reduce pain and swelling from conditions like arthritis, gout, and other inflammatory diseases. It works by decreasing inflammation in the body to help relieve discomfort.[1] Arcoxia is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Arcoxia is one of 168 small molecule programs targeting Asthma. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
175 competitors in Asthma
Arcoxia
Celexa
Paracetamol
Blood Withdrawn
Aclidinium Bromide
Ozone
Lexapro
Blood Collection
Biological Drug
Guanidine Hydrochloride
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources